References
1. Petroni ML, Brodosi L, Bugianesi E, Marchesini G.
Management of non-alcoholic fatty liver disease.
BMJ. 2021;372(1):1-8.
2. Eslam M, Sanyal AJ, George J, Sanyal A,
Neuschwander-Tetri B, Tiribelli C, et al. MAFLD: a
consensus-driven proposed nomenclature for
metabolic associated fatty liver disease.
Gastroenterol. 2020;158(7):1999-2014.
3. Kester MI, Teunissen CE, Crimmins DL, Herries
EM, Ladenson JH, Scheltens P, et al. Neurogranin as
a cerebrospinal fluid biomarker for synaptic loss in
symptomatic Alzheimer disease. JAMA Neurol.
2015;72(11):1275-80.
4. Hagström H, Nasr P, Ekstedt M, Hammar U,
Widman L, Stål P, et al. Health care costs of patients
with biopsy-confirmed nonalcoholic fatty liver
disease are nearly twice those of matched controls.
Clin Gastroenterol Hepatol. 2020;18(7):1592-99.
5. Canbay A, Taimr P, Torok N, Higuchi H, Friedman
S, Gores GJ. Apoptotic body engulfment by a human
stellate cell line is profibrogenic. Lab Invest.
2003;83(5):655-63.
6. Stefan N, Häring H, Cusi K. Non-alcoholic fatty
liver disease: causes, diagnosis, cardiometabolic
consequences, and treatment strategies. Lancet
Diabetes Endocrinol. 2019; 7 (4): 313-24.
7. Campos GM, Bambha K, Vittinghoff E, Rabl C,
Posselt AM, Ciovica R, et al. A clinical scoring
system for predicting nonalcoholic steatohepatitis in
morbidly obese patients. Hepatology.
2008;47(6):1916-23.
8. Chuah KH, Wan Yusoff WNI, Sthaneshwar P, Nik
Mustapha NR, Mahadeva S, Chan WK. MACK‐3
(combination of hoMa, Ast and CK18): a promising
novel biomarker for fibrotic non‐alcoholic
steatohepatitis. Liver Int. 2019;39(7):1315-24.
9. Ku NO, Strnad P, Bantel H, Omary MB. Keratins:
Biomarkers and modulators of apoptotic and necrotic
cell death in the liver. Hepatology. 2016;64(3):966-
976.
10. Hohmann T, Dehghani F. The cytoskeleton a
complex interacting meshwork. Cells. 2019;8(4):362-
73.
11. Chougule P, Sumitran-Holgersson S. Cytokeratins
of the liver and intestine epithelial cells during
development and disease. Cytokeratins. 2012(15):15-
32.
12. Teimouri N, Nayeri H. Serum cytokeratin-18
fragment levels, paraoxonase activity and lipid
profile of non-alcoholic fatty liver in iran. Iran Jour
Dia Met. 2016;15(3):183-91.
13. Van Der Windt DJ, Sud V, Zhang H, Tsung A,
Huang H. The effects of physical exercise on fatty
liver disease. Gene. 2018;18(2):89-97.
14.Nath P, Panigrahi MK, Sahu MK, Narayan J, Sahoo
RK, Patra AA, et al. Effect of exercise on NAFLD
and its risk factors: comparison of moderate versus
low intensity exercise. Clinical Hepatol.
2020;8(2):120-6.
15.Gabbia D, Cannella L, De Martin S. The role of
oxidative stress in NAFLD–NASH–HCC transition-
focus on NADPH oxidases. Biomedicines.
2021;9(6):687-98.
16. Hardwick RN, Fisher CD, Canet MJ, Lake AD,
Cherrington NJ. Diversity in antioxidant response
enzymes in progressive stages of human
nonalcoholic fatty liver disease. Drug.
2010;38(12):2293-301.
17. Abdelqader A, Obeidat M, Al-Rawashdeh M,
Alrazak A. The role of vitamin E as an antioxidant
and preventing damage caused by free radicals. Life
Science. 2023;4(2):88-95.
18. Podszun MC, Alawad AS, Lingala S, Morris N,
Huang W-CA, Yang S, et al. Vitamin E treatment in
NAFLD patients demonstrates that oxidative stress
drives steatosis through upregulation of de-novo
lipogenesis. Redox Biol. 2020;37(42):101-107.
19. Nagashimada M, Ota T. Role of vitamin E in
nonalcoholic fatty liver disease. IUBMB life.
2019;71(4):516-22.
20. Tahan G, Aytac E, Aytekin H, Gunduz F, Dogusoy
G, Aydin S, et al. Vitamin E has a dual effect of anti-
inflammatory and antioxidant activities in acetic
acid–induced ulcerative colitis in rats. Can J Surg.
2011;54(5):333-41.
21. Dowman JK, Tomlinson J, Newsome P.
Pathogenesis of non-alcoholic fatty liver disease.
QJM. 2010;103(2):71–83.
22. Barron-Cabrera E, Soria-Rodriguez R, Amador-
Lara F, Martinez-Lopez E, editors. Physical activity
protocols in non-alcoholic fatty liver disease
management: A systematic review of randomized
clinical trials and animal models. Healthcare (Basel).
2023;11(92):1-28.
23. Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M,
Azarbayjani MA. Mechanisms of beneficial effects
of exercise training on non-alcoholic fatty liver
disease (NAFLD): Roles of oxidative stress and
inflammation. Eur J Sport Sci. 2019;19(7):994-1003.
24. Fredrickson G, Barrow F, Dietsche K, Parthiban P,
Khan S, Robert S, et al. Exercise of high intensity
ameliorates hepatic inflammation and the progression
of NASH. Mol Metab. 2021;53(22):101-17.
25. Zhou T, Niu M, Liu R, Li L. Effect of aerobic
exercise on lipid metabolism in rats with NAFLD.
Front Genet. 2022;13(90):18-27.
26. Bae JY. Resistance exercise regulates hepatic
lipolytic factors as effective as aerobic exercise in
obese mice. Int J Environ Res Public Health.
2020;17(22):83-97.
27.Kalaki-Jouybari F, Shanaki M, Delfan M, Gorgani-
Firouzjae S, Khakdan S. High-intensity interval
training (HIIT) alleviated NAFLD feature via miR-
122 induction in liver of high-fat high-fructose diet
induced diabetic rats. Arch Physiol Biochem.
2020;126(3):242-9.
28.Luo X, Shi X, Sun Z, Xiao J, Song H, Lu G, et al.
GCN2 Deficiency Enhances Protective Effects of
Exercise on Hepatic Steatosis. Biomed Res Int.
2020;2020(1):145-51.
29. Ok D-P, Ko K, Bae JY. Exercise without dietary
changes alleviates nonalcoholic fatty liver disease
without weight loss benefits. Lipids Health Dis.
2018;17(1):207-18.
30. Wu B, Xu C, Tian Y, Zeng Y, Yan F, Chen A, et
al. Aerobic exercise promotes the expression of
ATGL and attenuates inflammation to improve
hepatic steatosis via lncRNA SRA. Sci Rep.
2022;12(1):5370-5386.
31. Shen J, Chan HY, Wong GH, Chan AH, Choi PL,
Chan HY, et al. Assessment of non‐alcoholic fatty
liver disease using serum total cell death and
apoptosis markers. Aliment Pharmacol Ther..
2012;36(11):1057-66.
32. Fealy CE, Haus JM, Solomon TP, Pagadala M,
Flask CA, McCullough AJ, et al. Short-term exercise
reduces markers of hepatocyte apoptosis in
nonalcoholic fatty liver disease. J Appl Physiol.
2012;113(1):1–6.
33. Handzlik MK, Shaw AJ, Dungey M, Bishop NC,
Gleeson M. The influence of exercise training status
on antigen-stimulated IL-10 production in whole
blood culture and numbers of circulating regulatory T
cells. J Appl Physiol. 2013;113(7):1839-1848.
34. Timmerman KL, Flynn MG, Coen PM, Markofski
MM, Pence BD. Exercise training-induced lowering
of inflammatory (CD14+ CD16+) monocytes: a role
in the anti-inflammatory influence of exercise? J
Leukoc Biol. 2008;84(5):1271-1278.
35. Hu X, Duan Z, Hu H, Li G, Yan S, Wu J, et al.
Proteomic profile of carbonylated proteins in rat
liver: exercise attenuated oxidative stress may be
involved in fatty liver improvement. Proteomics.
2013;13(10):1755-64.
36. Da Luz G, Frederico MJ, da Silva S, Vitto MF,
Cesconetto PA, de Pinho RA, et al. Endurance
exercise training ameliorates insulin resistance and
reticulum stress in adipose and hepatic tissue in
obese rats. Eur J Appl Physiol. 2011;111(9):2015-23.
37. Rosa-Caldwell ME, Lee DE, Brown JL, Brown LA,
Perry Jr RA, Greene ES, et al. Moderate physical
activity promotes basal hepatic autophagy in diet-
induced obese mice. Appl Physiol Nutr Metab.
2017;42(2):148-56.
38. Wu Y, Zhou J, Zhang J, Li H. Cytokeratin 18 in
nonalcoholic fatty liver disease: value and
application. Expert Rev Mol Diagn.
2024;24(11):1009-22.
39. HajGhasem A, Mazaheri Z. Effects of combined
therapy with resveratrol, continuous and interval
exercises on apoptosis and lipid profiles in the liver
of rats with nonalcoholic fatty liver disease. Arch
Physiol Biochem. 2019;125(2):142-9.
40. Korver S, Bowen J, Pearson K, Gonzalez RJ,
French N, Park K, et al. The application of
cytokeratin-18 as a biomarker for drug-induced liver
injury. Arch Toxicol. 2021;95(11):3435-48.
41. Rajabi S, Askari R, Haghighi AH, Razaviyanzadeh
N. Effect of resistance-interval training with two
different intensities on cytokeratin18 and some
functional parameters in women with fatty liver.
Obstetrics. 2020;23(3):68–81.
42. Nan Y-M, Wu W-J, Fu N, Liang B-L, Wang R-Q,
Li L-X, et al. Antioxidants vitamin E and 1-
aminobenzotriazole prevent experimental non-
alcoholic steatohepatitis in mice. Scand J
Gastroenterol. 2009;44(9):1121-31.
43. Phung N, Pera N, Farrell G, Leclercq I, Hou JY,
George J. Pro-oxidant-mediated hepatic fibrosis and
effects of antioxidant intervention in murine dietary
steatohepatitis. Int J Mol Med. 2009;24(2):171-80.
44. Sanyal AJ, Chalasani N, Kowdley KV,
McCullough A, Diehl AM, Bass NM, et al.
Pioglitazone, vitamin E, or placebo for nonalcoholic
steatohepatitis. N Engl J Med. 2010;362(18):1675-
85.
45. Dyson JK, Anstee QM, McPherson S. Non-
alcoholic fatty liver disease: a practical approach to
diagnosis and staging. Frontline Gastroenterol.
2014;5(3):211-8
مجله علوم پزشکی پارس